Neumora Therapeutics, Inc.: updates and filings

NMRANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.33

November 20, 2026Market cap $61M

What Ploutos Investor adds for Neumora Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 30, 2026 latest annualNov 16, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 16, 2026Results of operations
    Form8-K
  • Oct 30, 2026Delisting notice
    Form8-K
  • Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 14, 2026Results of operations, officer or director change
    Form8-K
  • Jul 27, 2026Other material events
    Form8-K
  • Jun 15, 2026Material agreement entered, new material financial obligation, restructuring costs, Regulation FD disclosure, other material events
    Form8-K
  • May 29, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations
    Form8-K
  • May 4, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 17, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 17, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 1, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Mar 30, 2026Shares registered for employees
    FormS-8
  • Mar 30, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 30, 2026Results of operations
    Form8-K
  • Feb 19, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 11, 2026Regulation FD disclosure
    Form8-K
  • Jan 12, 2026Regulation FD disclosure
    Form8-K
  • Jan 5, 2026Other material events
    Form8-K
  • Nov 21, 2025Unregistered sale of shares
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 8, 2021.

The full analysis

What do Neumora Therapeutics's filings show?

The filings are where every one of Neumora Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.